生物
RNA提取
核糖核酸
病毒学
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
2019年冠状病毒病(COVID-19)
遗传学
基因
传染病(医学专业)
病理
医学
疾病
作者
Emily A. Bruce,Meei‐Li Huang,Garrett A. Perchetti,Scott Tighe,Pheobe Laaguiby,Jessica Hoffman,Diana L. Gerrard,Arun Kumar Nalla,Yulun Wei,Alexander L. Greninger,Sean A. Diehl,David J. Shirley,Debra G. B. Leonard,Christopher D. Huston,Beth D. Kirkpatrick,Julie A. Dragon,Jessica W. Crothers,Keith R. Jerome,Jason Botten
出处
期刊:PLOS Biology
[Public Library of Science]
日期:2020-10-02
卷期号:18 (10): e3000896-e3000896
被引量:196
标识
DOI:10.1371/journal.pbio.3000896
摘要
The ongoing COVID-19 pandemic has created an unprecedented need for rapid diagnostic testing. The World Health Organization (WHO) recommends a standard assay that includes an RNA extraction step from a nasopharyngeal (NP) swab followed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) to detect the purified SARS-CoV-2 RNA. The current global shortage of RNA extraction kits has caused a severe bottleneck to COVID-19 testing. The goal of this study was to determine whether SARS-CoV-2 RNA could be detected from NP samples via a direct RT-qPCR assay that omits the RNA extraction step altogether. The direct RT-qPCR approach correctly identified 92% of a reference set of blinded NP samples (n = 155) demonstrated to be positive for SARS-CoV-2 RNA by traditional clinical diagnostic RT-qPCR that included an RNA extraction. Importantly, the direct method had sufficient sensitivity to reliably detect those patients with viral loads that correlate with the presence of infectious virus. Thus, this strategy has the potential to ease supply choke points to substantially expand COVID-19 testing and screening capacity and should be applicable throughout the world.
科研通智能强力驱动
Strongly Powered by AbleSci AI